Proven Intelligence in Gene Editing Safety Assessment.

Executive Summary

For base editor and prime editor therapeutics, demonstrating target specificity is a primary component of the preclinical safety program. Regulatory bodies require empirical, GxP-compliant data to rule out clinically significant off-target editing events. This involves a multi-tiered strategy that moves from initial computational predictions to unbiased genome-wide screening and finally to targeted deep sequencing in relevant in vivo models to quantify liabilities. Franklin Biolabs provides the validated analytical frameworks and IND-enabling toxicology study designs required to build a comprehensive safety profile for these precision editors.

A Data-Driven Preclinical Strategy for Base Editors

The development of base and prime editors represents a significant advance in the precision of gene editing. Unlike nuclease platforms that induce double-stranded breaks, these systems mediate direct chemical conversions of nucleotide bases. This mechanism, however, introduces a unique set of potential off-target activities, including bystander edits near the target site and guide-independent modifications, which demand a tailored analytical safety strategy.

A standard preclinical template does not exist for these next-generation therapies. An IND-enabling program must be designed based on the specific editor, delivery system (e.g., LNP, AAV), and target indication.

Multi-Tiered Analytical Approach for Off-Target Detection

A robust safety assessment moves beyond simple computational predictions to generate empirical evidence under GxP conditions. This process is structured to systematically identify and quantify risk.

• Tier 1: Unbiased Genome-Wide Identification. In vitro screening assays like CHANGE-seq or GUIDE-seq are performed on appropriate cell lines to create a comprehensive, unbiased map of potential off-target loci across the genome.

• Tier 2: Targeted Sequencing for Prioritization. The nominated sites from Tier 1 are then evaluated using highly sensitive targeted deep sequencing. This step quantifies the frequency of off-target editing at each location, allowing for prioritization based on potential clinical impact.

• Tier 3: In Vivo Confirmation. The highest-priority off-target sites are assessed in biological samples from definitive IND-enabling toxicology studies. This provides the most relevant context for regulatory evaluation.